First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer
ID : NCT02716012 – MNA-3521-011 – 2015-003051-21 EudraCT Number) – 20332 (Other Identifier: UK NIHR CRN) – OUTREACH
Mina Therapeutics (UK)
Product: MTL-CEBPA (Small activating RNA (saRNA) – short double stranded RNA designed to activate CCAAT enhancer binding protein alpha (CEBPA) gene)
Start/Planned completion: MAR 2016/DEC 2019
Estimated Enrollment: 51
Sites: 9 (SG, TW, UK)
Updated: September 10, 2018
The study is in two parts: dose escalation followed by a dose expansion; both parts of the study will recruit advanced hepatocellular carcinoma patients with cirrhosis. All participants will be refractory to or ineligible for loco-regional therapy including surgery, radiofrequency tumour ablation, transarterial chemoembolisation or sorafenib.
* DEC 2018 – MiNA Therapeutics announced enrolment of the first patients treated with MTL-CEBPA in combination with Sorafenib in OUTREACH
Link: Press Release
* Oncol Rep. 2018 Dec 13. doi: 10.3892/or.2018.6930.
MicroRNA‑486‑5p functions as a tumor suppressor of proliferation and cancer stem‑like cell properties by targeting Sirt1 in liver cancer. Yan X et al. College of Life Science and Bioengineering, Beijing University of Technology, Beijing, CN.
– Results/Comments : MicroRNAs are small non‑coding RNAs that target the 3’untranslated region of mRNAs. Their dysregulation has been implicated in several types of cancer including liver cancer, but it still remains unknown if they play a role in targeting liver cancer stem‑like cells (CSCs). These researchers compared the miRNA profiles between liver cancer samples and adjacent non‑tumor tissues using The Cancer Genome Atlas (TCGA) datasets. The results of their study indicated that the miR‑486‑Sirt1 axis was involved in suppressing CSC traits and tumor progression.
* Oncol Rep . 2018 Dec 12. doi: 10.3892/or.2018.6928.
Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy. Hou JZ et al. Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, Henan, CN.
– Results/Comments : This study incidates that phosphatidylinositol‑3‑phosphate 5‑kinase (PIKfyve) may be a potential therapeutic target for the treatment of liver cancer. Link: Abstract
* OCT 2018 – MiNA Therapeutics announces Sosei will not exercise acquisition option. Link: Press Release
* SEP 2018 – MiNA Therapeutics provided an update from the ongoing Phase I study of MTL-CEBPA in advanced liver cancer patients at International Liver Cancer Association Conference. Link: Press Release